Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hansa Biopharma AB ( (SE:HNSA) ) has shared an announcement.
Hansa Biopharma announced its CEO, Renée Aguiar-Lucander, will participate in key discussions at the Jefferies Global Healthcare Conference in London and the DNB Carnegie’s 16th Annual Nordic Healthcare Conference in Oslo. These engagements are significant for Hansa Biopharma as they provide a platform to showcase its innovative treatments and strengthen its industry positioning, potentially impacting stakeholder relations and market perception.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK132.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company utilizes its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy for enabling kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma operates in Europe and the U.S. and is listed on Nasdaq Stockholm.
Average Trading Volume: 677,609
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.7B
For an in-depth examination of HNSA stock, go to TipRanks’ Overview page.